moxisylyte

CLINICAL USE

Primary Raynaud’s syndrome

DOSE IN NORMAL RENAL FUNCTION

40–80 mg 4 times daily

PHARMACOKINETICS

Molecular weight :315.8

%Protein binding :No data

%Excreted unchanged in urine : <1

Volume of distribution (L/kg) :Low1

half-life – normal/ESRD (hrs) :1–2

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

25–50 Dose as in normal renal function10–25 Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in normal renal function

HD :Unlikely to be dialysed. Dose as in normal renal function

HDF/high flux :Unlikely to be dialysed. Dose as in normal renal function

CAV/VVHD :Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsAlpha-blockers: possibly severe postural hypotension when given in combination

Beta-blockers: possibly severe postural hypotension when given in combination

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Theoretically may decrease insulin requirements in diabetics

Tags: post-by-auto-php